Ethical Considerations When Managing Patients' Pain

Gain an understanding of how to help maintain the proper ethical pain management of patients. We are practicing in the midst of a national crisis in which every day over 130 people in the US die of overdosing from narcotic prescriptions overdose, heroin, and other related drugs. The pain was described as the "5th vital sign" by some drug companies in the 1990s and stated that patients would not be addicted to pain killers and providers began to overprescribe them in order to adequately treat pain. Approximately one-third of the chronic opioid user for none malignant pains misuse them. The incidence of neonatal abstinence syndrome has been on the rise due to widespread opioid use. CDC has published new guidelines as for how to counteract this crisis and regulatory agencies including states medical boards and DEA has increased enforcement against irresponsible and fraudulent opioid prescription writers to include license revocations and jail terms.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

De-Risky Business: Assessing Biotherapeutic Off-Target and On-Target Liabilities

genengnews

De-Risky Business: Assessing Biotherapeutic Off-Target and On-Target Liabilities Toxicity failures caused by off-target or unintended on-target liabilities are a leading cause of attrition in clinical and preclinical programs. Given the effort, cost, and technical limitations of traditional biopharmaceutical de-risking strategies, there is a need for a robust and scalable approach that can be rapidly applied to the discovery phases of therapeutic programs. Join us for this exciting new GEN Webinar, where our panel of experts will discuss new approaches to de-risking lead selection of antibodies and other biotherapeutics.
Watch Now

Custom LNP formulation development - The new Early Formulation Screening Service as a key partner for success

Nucleic acids are known to be fragile payloads. To enable their safe and efficient delivery into cells, the RNA payload needs to be “packed” into a delivery vehicle, the lipid nanoparticles (LNP). This webinar gives insight into our capabilities for customized LNP formulation development for novel therapeutic modalities.
Watch Now

Exclusive Live Interviews with Biotech Executives from GEN EDGE

In this Close to the Edge new live series, we’ll be interviewing chief executives and scientific and business leaders from the biotech spectrum. In this inaugural episode on May 12 GEN Edge welcomes Christian Henry, the CEO of PacBio, for an exclusive interview.
Watch Now

Material Requirements to Support Gene Therapy Development

Manufacturing processes for gene therapy products are generally low yielding compared to production processes for other biologics.
Watch Now

Spotlight

resources